MX2016000900A - Nuevos derivados de indol y de pirrol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. - Google Patents

Nuevos derivados de indol y de pirrol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.

Info

Publication number
MX2016000900A
MX2016000900A MX2016000900A MX2016000900A MX2016000900A MX 2016000900 A MX2016000900 A MX 2016000900A MX 2016000900 A MX2016000900 A MX 2016000900A MX 2016000900 A MX2016000900 A MX 2016000900A MX 2016000900 A MX2016000900 A MX 2016000900A
Authority
MX
Mexico
Prior art keywords
indole
pyrrole
production
pharmaceutical compositions
compositions containing
Prior art date
Application number
MX2016000900A
Other languages
English (en)
Other versions
MX364479B (es
Inventor
Guillaume De Nanteuil
Patrick Casara
Thierry Le Diguarher
Olivier Geneste
Jérôme-Benoît Starck
Jean-Michel Henlin
James Edward Paul Davidson
I-Jen Chen
Christopher John Graham
Arnaud Le Tiran
Claire Walmsley
Stuart Ray
Daniel Maddox
Simon Bedford
James Brooke Murray
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of MX2016000900A publication Critical patent/MX2016000900A/es
Publication of MX364479B publication Critical patent/MX364479B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Abstract

Compuestos de fórmula (I): (ver Fórmula) en la que Ra, Rb, Rc, Rd, R3, R4, R5, A1, A2, T y W son tales como se han definido en la descripción.
MX2016000900A 2013-07-23 2014-07-22 Nuevos derivados de indol y de pirrol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. MX364479B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1357277A FR3008978A1 (fr) 2013-07-23 2013-07-23 "nouveaux derives d'indole et de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
PCT/FR2014/051884 WO2015011396A1 (fr) 2013-07-23 2014-07-22 Nouveaux derives d'indole et de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (2)

Publication Number Publication Date
MX2016000900A true MX2016000900A (es) 2016-05-05
MX364479B MX364479B (es) 2019-04-29

Family

ID=49911607

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016000900A MX364479B (es) 2013-07-23 2014-07-22 Nuevos derivados de indol y de pirrol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.

Country Status (31)

Country Link
US (2) US9765056B2 (es)
EP (2) EP3027602B1 (es)
JP (1) JP6458028B2 (es)
KR (1) KR102337149B1 (es)
CN (1) CN105408321B (es)
AR (1) AR099914A1 (es)
AU (1) AU2014294866B2 (es)
BR (1) BR112016001333B1 (es)
CA (1) CA2917965C (es)
CY (1) CY1120475T1 (es)
DK (1) DK3027602T3 (es)
EA (1) EA028609B1 (es)
ES (1) ES2687475T3 (es)
FR (1) FR3008978A1 (es)
HK (1) HK1218753A1 (es)
HR (1) HRP20181333T1 (es)
HU (1) HUE039507T2 (es)
LT (1) LT3027602T (es)
MX (1) MX364479B (es)
NZ (1) NZ715847A (es)
PL (1) PL3027602T3 (es)
PT (1) PT3027602T (es)
RS (1) RS57545B1 (es)
RU (1) RU2693404C2 (es)
SG (1) SG11201600004SA (es)
SI (1) SI3027602T1 (es)
TW (1) TW201504224A (es)
UA (1) UA117020C2 (es)
UY (1) UY35653A (es)
WO (1) WO2015011396A1 (es)
ZA (1) ZA201600415B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105237509A (zh) * 2015-11-20 2016-01-13 江苏瑞邦农药厂有限公司 一种2,2-二氟-1,3-苯并二恶茂的合成方法
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
CA3049728A1 (en) * 2017-01-10 2018-07-19 Eth Zurich Inhibitors of g-protein-coupled receptor kinase 2 and their use
US11530254B2 (en) 2017-03-31 2022-12-20 The University Of Tokyo Norovirus antibody
CN108409580A (zh) * 2018-02-01 2018-08-17 浙江工业大学 一种苄胺类化合物的合成方法
CN113453679A (zh) 2018-12-20 2021-09-28 C4医药公司 靶向蛋白降解
WO2023225359A1 (en) 2022-05-20 2023-11-23 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070060596A1 (en) 2003-10-24 2007-03-15 Giblin Gerard M P Heterocyclyl compounds
TW200533398A (en) * 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
CA2577752A1 (en) * 2004-08-20 2006-03-02 The Regents Of The University Of Michigan Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof
GB0522908D0 (en) 2005-11-10 2005-12-21 Merck Sharp & Dohme Therapeutic agents
EP2714681B1 (en) * 2011-05-25 2015-06-24 Bristol-Myers Squibb Company Substituted sulfonamides useful as antiapoptotic bcl inhibitors
EP2794592A1 (en) * 2011-12-23 2014-10-29 Novartis AG Compounds for inhibiting the interaction of bcl2 with binding partners
AU2012355613A1 (en) * 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
JP2015503516A (ja) * 2011-12-23 2015-02-02 ノバルティス アーゲー Bcl2と結合相手の相互作用を阻害するための化合物
EP2794591A1 (en) * 2011-12-23 2014-10-29 Novartis AG Compounds for inhibiting the interaction of bcl2 with binding partners
JP2015503517A (ja) * 2011-12-23 2015-02-02 ノバルティス アーゲー Bcl2と結合相手の相互作用を阻害するための化合物
FR2986002B1 (fr) 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
CN105408321A (zh) 2016-03-16
JP6458028B2 (ja) 2019-01-23
TW201504224A (zh) 2015-02-01
HK1218753A1 (zh) 2017-03-10
FR3008978A1 (fr) 2015-01-30
US20170342051A1 (en) 2017-11-30
SG11201600004SA (en) 2016-02-26
AU2014294866B2 (en) 2018-09-27
US10662173B2 (en) 2020-05-26
HUE039507T2 (hu) 2019-01-28
WO2015011396A1 (fr) 2015-01-29
BR112016001333B1 (pt) 2022-03-03
US9765056B2 (en) 2017-09-19
LT3027602T (lt) 2018-07-25
AU2014294866A1 (en) 2016-02-04
CA2917965C (fr) 2018-03-06
SI3027602T1 (en) 2018-08-31
EP3027602B1 (fr) 2018-06-13
RS57545B1 (sr) 2018-10-31
AR099914A1 (es) 2016-08-31
EP3168217A1 (fr) 2017-05-17
PL3027602T3 (pl) 2018-10-31
EA201600121A1 (ru) 2016-07-29
NZ715847A (en) 2019-06-28
CY1120475T1 (el) 2019-07-10
RU2693404C2 (ru) 2019-07-02
UY35653A (es) 2015-02-27
CN105408321B (zh) 2019-03-08
KR20160034384A (ko) 2016-03-29
CA2917965A1 (fr) 2015-01-29
MX364479B (es) 2019-04-29
RU2016106002A3 (es) 2018-03-19
US20160152599A1 (en) 2016-06-02
HRP20181333T1 (hr) 2018-10-19
BR112016001333A2 (es) 2017-07-25
UA117020C2 (uk) 2018-06-11
ES2687475T3 (es) 2018-10-25
EP3027602A1 (fr) 2016-06-08
JP2016531108A (ja) 2016-10-06
DK3027602T3 (en) 2018-09-24
PT3027602T (pt) 2018-07-23
ZA201600415B (en) 2017-03-29
KR102337149B1 (ko) 2021-12-07
EA028609B1 (ru) 2017-12-29
RU2016106002A (ru) 2017-08-30

Similar Documents

Publication Publication Date Title
JO3275B1 (ar) مشتقات بيرول جديدة وطريقة لتحضيرها وتركيبات صيدلانية التي تحتوي عليها
MX2016000900A (es) Nuevos derivados de indol y de pirrol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
EA201400833A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
MY190243A (en) Hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
JO3675B1 (ar) مشتقات هيدروكسي إستر جديدة،عملية لتحضيرها وتركيبات صيدلية تحتوي عليها
MX2016000906A (es) Nuevos derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
PH12015501996A1 (en) Heterocyclic compounds and uses thereof
MX2015013042A (es) Compuestos organicos.
EA201401292A2 (ru) Новые тиенопиримидиновые производные, способ их получения и фармацевтические композиции, содержащие их
JO3160B1 (ar) مشتقات الفوسفات الجديدة, طريقة تحضيرها والتركيبات الدوائية التي تحتوي عليها
MD4664B1 (ro) Lactame aril şi heteroaril condensate
MY180165A (en) Heteroaryl butanoic acid derivatives as lta4h inhibitors
EA201600122A1 (ru) Новые изоиндолиновые или изохинолиновые соединения, способ их получения и фармацевтические композиции, содержащие их
IN2015DN00950A (es)
MX2013013436A (es) Derivados de indol sustituidos para el tratamiento de transtornos inmunologicos.
IN2015DN02660A (es)
EA201892831A1 (ru) Новые (гетеро)арил-замещенные пиперидинильные производные, способ их получения и фармацевтические композиции, содержащие их
IN2013CH05769A (es)
IN2013CH05770A (es)

Legal Events

Date Code Title Description
FG Grant or registration